Volume Spike Investor

Human Genome Sciences Inc. (Nasdaq: HGSI) shares are up 17 percent to $14.72, on about 10 times average volume. The company late Monday said its Benlysta lupus treatment candidate met its primary and secondary endpoints. Analysts at ThinkEquity said the data favor approval, which could make it the first FDA-approved lupus therapy in more than 30 years. The drug still needs to complete another late-stage trial, and is not expected to be approved until late 2010, at the earliest.